GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Aztreonam

GlobalRPh source pageBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Professional source

UCSF - systemic aztreonam

Product / population
Adults; single-agent systemic IV aztreonam. Combination-use comments are specialist-specific.
Renal measure
CrCl in mL/min where specified; no equation inferred.

Dosing / renal protocol and limits

IV regimen by CrCl: above 50, 2 g every 8 hours; 10-50, 2 g every 12 hours; below 10, 1 g every 12 hours. IHD: 2 g initially, then each evening. CVVHD: 2 g every 12 hours.

Selected meningitis or resistant Gram-negative cases may require 2 g every 6 hours under specialist direction. When combined with ceftazidime/avibactam for selected resistant infections, both may be infused over 3 hours; simultaneous dosing is preferred when intervals coincide. This is a systemic aztreonam protocol, not inhaled aztreonam or fixed-combination EMBLAVEO.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://idmp.ucsf.edu/content/aztreonam

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - systemic aztreonam

Adults; single-agent systemic IV aztreonam. Combination-use comments are specialist-specific.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeUCSF - systemic aztreonam
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Systemic aztreonam only; not inhaled aztreonam lysine. The original 125 mg dialysis comment is not one-eighth of every possible initial dose; the source paragraph specifies one-eighth of the initial dose. Both are preserved as a source discrepancy.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/aztreonam/

Usual Dosing (Adults)

[Mild infection] (i.e. UTI): 500mg to 1 gram IV q8-12h.

[Usual dose]: 1-2 grams IV q8-12h.

[Severe/life threatening infection]: 2 grams IV q6-8h. [Maximum dose]: 8 grams/day.

DOSAGE AND ADMINISTRATION - Dosage in Adult Patients

AZACTAM may be administered intravenously or by intramuscular injection. Dosage and route of administration should be determined by susceptibility of the causative organisms, severity and site of infection, and the condition of the patient. The intravenous route is recommended for patients requiring single doses greater than 1 g or those with bacterial septicemia, localized parenchymal abscess (eg, intra-abdominal abscess), peritonitis or other severe systemic or life-threatening infections.

The duration of therapy depends on the severity of infection. Generally, AZACTAM should be continued for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. Persistent infections may require treatment for several weeks. Doses smaller than those indicated should not be used.

AZACTAM DOSAGE GUIDELINES - ADULTS

Type of infectionDoseFrequency (hours)
Urinary tract infections500 mg or 1 g8 or 12
Moderately severe systemic infections1 g or 2 g8 or 12
Severe systemic or life-threatening infections2 g6 or 8

Maximum recommended dose is 8 g per day.

Because of the serious nature of infections due to Pseudomonas aeruginosa, dosage of 2 g every 6 or 8 hours is recommended, at least upon initiation of therapy, in systemic infections caused by this organism in adults.

GRPH-aztreonam-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

IV:

[CRCL >30 ml/min]: no change.

[10-30 ml/min]: Loading dose: 1-2 grams x 1, then give 50% of the usual dose (e.g. 0.5-1 gm) q6-12h.

[<10 ml/min]: 1-2 grams x 1, then 25% of usual dose (e.g. 250-500 mg) q6-12 hours.

Renal Impairment in Adult Patients

Prolonged serum levels of aztreonam may occur in patients with transient or persistent renal insufficiency. Therefore, the dosage of AZACTAM should be halved in patients with estimated creatinine clearances between 10 mL/min/1.73 m2 and 30 mL/min/1.73 m2 after an initial loading dose of 1 g or 2 g. When only the serum creatinine concentration is available, the following formula (based on sex, weight, and age of the patient) may be used to approximate the creatinine clearance (Clcr).

The serum creatinine should represent a steady state of renal function.

Males: Clcr = [weight (kg) x (140-age)] / [72 x serum creatinine (mg/dL)]

Females: 0.85 x above value

In patients with severe renal failure (creatinine clearance less than 10 mL/min/1.73 m2), such as those supported by hemodialysis, the usual dose of 500 mg, 1 g or 2 g should be given initially. The maintenance dose should be one-fourth of the usual initial dose given at the usual fixed interval of 6, 8 or 12 hours. For serious or life-threatening infections, in addition to the maintenance doses, one-eighth of the initial dose should be given after each hemodialysis session.

GRPH-aztreonam-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Hemodialysis:

1-2 grams x 1, then 25% of usual dose q6-12h. (e.g., 250-500 mg q6-12 hours).

For serious or life-threatening infections, give an additional 125mg after each hemodialysis session (1/8th of the usual dose).

PD: 1-2 grams x 1, then 25% of usual dose q6-12h. (e.g., 250-500 mg q6-12 hours).

GRPH-aztreonam-03 · Source section: HemodialysisRenal section finder
Separate professional-source layer

University and professional protocols

Professional

UCSF - systemic aztreonam

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; single-agent systemic IV aztreonam. Combination-use comments are specialist-specific.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

IV regimen by CrCl: above 50, 2 g every 8 hours; 10-50, 2 g every 12 hours; below 10, 1 g every 12 hours. IHD: 2 g initially, then each evening. CVVHD: 2 g every 12 hours.

Selected meningitis or resistant Gram-negative cases may require 2 g every 6 hours under specialist direction. When combined with ceftazidime/avibactam for selected resistant infections, both may be infused over 3 hours; simultaneous dosing is preferred when intervals coincide. This is a systemic aztreonam protocol, not inhaled aztreonam or fixed-combination EMBLAVEO.

RDM30-003-aztreonam-1 · Source locator: UCSF - systemic aztreonam; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/aztreonam
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
9365c1f0040a336429593cb3cb7adbcdee676e02dd584559897afb2532007056

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/aztreonam/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
7bffacfa7543698e7753f5cc3bf44699069aadf6ba664e31920d14a8100a683e
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report